Profile of clinical and analytical parameters in bronchiectasis patients during the COVID-19 pandemic: a one-year follow-up pilot study

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Qin, Liyun
• dc.contributor.author Gonçalves-Carvalho, Filipe
• dc.contributor.author Xia, Yingchen
• dc.contributor.author Zha, Jianhua
• dc.contributor.author Admetlló Papiol, Mireia
• dc.contributor.author Maiques Llácer, José María
• dc.contributor.author Esteban-Cucó, Sandra
• dc.contributor.author Duran Jordà, Xavier, 1974-
• dc.contributor.author Marín, Alicia
• dc.contributor.author Barreiro Portela, Esther
• dc.date.accessioned 2022-09-30T05:51:34Z
• dc.date.available 2022-09-30T05:51:34Z
• dc.date.issued 2022
• dc.description.abstract Whether the COVID-19 pandemic may have modified the clinical planning and course in bronchiectasis patients remains to be fully elucidated. We hypothesized that the COVID-19 pandemic may have influenced the management and clinical outcomes of bronchiectasis patients who were followed up for 12 months. In bronchiectasis patients (n = 30, 23 females, 66 years), lung function testing, disease severity [FEV1, age, colonization, radiological extension, dyspnea (FACED), exacerbation (EFACED)] and dyspnea scores, exacerbation numbers and hospitalizations, body composition, sputum microbiology, and blood analytical biomarkers were determined at baseline and after a one-year follow-up. Compared to baseline (n = 27, three patients dropped out), in bronchiectasis patients, a significant increase in FACED and EFACED scores, number of exacerbations, and erythrocyte sedimentation rate (ESR) was observed, while FEV1, ceruloplasmin, IgE, IgG, IgG aspergillus, IgM, and IgA significantly decreased. Patients presenting colonization by Pseudomonas aeruginosa (PA) remained unchanged (27%) during follow-up. In bronchiectasis patients, FEV1 declined only after a one-year follow-up along with increased exacerbation numbers and disease severity scores, but not hospitalizations. However, a significant decrease in acute phase-reactants and immunoglobulins was observed at the one-year follow-up compared to baseline. Despite the relatively small cohort, the reported findings suggest that lung function impairment may not rely entirely on the patients' inflammatory status.
• dc.format.mimetype application/pdf
• dc.identifier.citation Qin L, Gonçalves-Carvalho F, Xia Y, Zha J, Admetlló M, Maiques JM, Esteban-Cucó S, Duran X, Marín A, Barreiro E. Profile of clinical and analytical parameters in bronchiectasis patients during the COVID-19 pandemic: a one-year follow-up pilot study. J Clin Med. 2022 Mar 21;11(6):1727. DOI: 10.3390/jcm11061727
• dc.identifier.doi http://dx.doi.org/10.3390/jcm11061727
• dc.identifier.issn 2077-0383
• dc.identifier.uri http://hdl.handle.net/10230/54232
• dc.language.iso eng
• dc.publisher MDPI
• dc.relation.ispartof J Clin Med. 2022 Mar 21;11(6):1727
• dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri https://creativecommons.org/licenses/by/4.0/
• dc.subject.keyword Immunoglobulins
• dc.subject.keyword Lung function
• dc.subject.keyword Non-cystic fibrosis bronchiectasis
• dc.subject.keyword Nutritional status
• dc.subject.keyword One-year follow-up
• dc.subject.keyword Severity scores
• dc.subject.keyword Systemic inflammation
• dc.subject.keyword Immunoglobulins
• dc.title Profile of clinical and analytical parameters in bronchiectasis patients during the COVID-19 pandemic: a one-year follow-up pilot study
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion